Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty - Wesley Research Institute
Wesley Research Institute
Donate
Now

Improving patient outcomes for Knee Arthroplasty

Research Objectives

Status

Current

Estimated completion

December 2023

Total participants required

80

Study location

The Wesley Hospital

About this clinical trial

The number of people undergoing total knee arthroplasty (TKA) for osteoarthritis has been steadily increasing in Australia. There is a significant risk of blood loss during this procedure, resulting in prolonged hospital stay, pain and poor functional outcomes.

The purpose of this trial is to evaluate the effects of oral Tranexamic Acid (TXA) when administered pre-operatively.

The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of a blood transfusion and may decrease pain, swelling and recovery time following the operation.

Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about how to dose individual patients with this medication to achieve the best results.

This study will assess whether different treatment durations and doses will lead to better patient outcomes.

Eligibility

Do you meet the following criteria?

People undergoing primary unilateral Total Knee Arthroplasty.

Additional information

You can find out more about this clinical trial by visiting the ANZCTR website.

Lead investigators

  • Dr Sue Clark

Technical title

A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty

Register your interest

If you would like more information about this clinical trial, please complete the contact form below.

Name(Required)
Address(Required)
DD slash MM slash YYYY
Which if the following accurately describes you?(Required)

Would you like to be updated on the progress of our research?(Required)
By submitting this form you consent for us to hold your information in accordance with our Privacy Policy
This field is for validation purposes and should be left unchanged.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram